Vivus reports Qnexa phase 3 study results

Vivus, a developer of therapies to address obesity, sleep apnea, diabetes and male sexual health, has reported the data of Qnexa in its Phase 3 study.Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase satiety and to address weight loss, type 2 diabetes and obstructive sleep apnea. The company said improvements in quality of life were measured using two validated surveys they are the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and Medical Outcomes Study Short Form-36 (SF-36).The IWQOL-Lite instrument was administered to all patients in the Equip and Conquer studies.The SF-36 was administered to all patients in the Conquer clinical study.

Duke University Medical Center Obesity and Quality of Life Consulting Consulting professor Ronette Kolotkin said the patients treated with Qnexa during the 56-week Equip and Conquer trials showed improvements in quality of life compared to placebo patients.